Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Silicon containing doai
Patent
1991-06-25
1993-07-06
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Silicon containing doai
514291, 514411, 540452, 540456, 435118, 435886, 435898, A01N 5500, A61K 31695
Patent
active
052254038
ABSTRACT:
Described is a process for producing a new FK-506 antagonist agent, a C-21 hydroxylated analog of FR-900520 under novel fermentation conditions utilizing the novel microorganism, Streptomyces hygroscopicus (Merck Culture Collection MA 6832) ATCC No. 55166. The macrolide antagonist is useful in preventing and/or counteracting accidental or inadvertent FK-506 overdosage in an FK-506 therapeutic program designed to prevent autoimmune diseases or human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
REFERENCES:
patent: 3244592 (1966-04-01), Arai et al.
patent: 4894366 (1990-01-01), Okuhara et al.
patent: 5064835 (1991-11-01), Bochis et al.
Arison Byron H.
Colwell, Jr. Lawrence F.
Dezeny Georgette
Dumont Francis
Treiber Laszlo R.
Caruso Charles M.
DiPrima Joseph F.
Merck & Co. , Inc.
North Robert J.
Nutter Nathan M.
LandOfFree
C-21 hydroxylated FK-506 antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-21 hydroxylated FK-506 antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-21 hydroxylated FK-506 antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1689675